BG63744B1 - Използване на аналог на валпроева киселина за лечение и профилактика на мигрена и афективни заболявания - Google Patents
Използване на аналог на валпроева киселина за лечение и профилактика на мигрена и афективни заболявания Download PDFInfo
- Publication number
- BG63744B1 BG63744B1 BG105163A BG10516301A BG63744B1 BG 63744 B1 BG63744 B1 BG 63744B1 BG 105163 A BG105163 A BG 105163A BG 10516301 A BG10516301 A BG 10516301A BG 63744 B1 BG63744 B1 BG 63744B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- propyl
- acid
- compound
- hexic
- migraine
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title claims abstract description 37
- 238000011282 treatment Methods 0.000 title claims abstract description 22
- 206010027599 migraine Diseases 0.000 title claims abstract description 11
- 230000002265 prevention Effects 0.000 title claims abstract description 10
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical class CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 40
- 239000002253 acid Substances 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000017194 Affective disease Diseases 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 206010026749 Mania Diseases 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 239000003182 parenteral nutrition solution Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 40
- 229940079593 drug Drugs 0.000 abstract description 35
- 239000003814 drug Substances 0.000 abstract description 35
- 230000002829 reductive effect Effects 0.000 abstract description 12
- 230000002460 anti-migrenic effect Effects 0.000 abstract description 3
- 206010029350 Neurotoxicity Diseases 0.000 abstract description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract description 2
- 231100000228 neurotoxicity Toxicity 0.000 abstract description 2
- 230000007135 neurotoxicity Effects 0.000 abstract description 2
- VWPXMGURRCAAAR-UHFFFAOYSA-N 2-propylhex-3-ynoic acid Chemical compound CCCC(C(O)=O)C#CCC VWPXMGURRCAAAR-UHFFFAOYSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 description 38
- 210000004727 amygdala Anatomy 0.000 description 24
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical class [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 24
- 229960000604 valproic acid Drugs 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 208000019022 Mood disease Diseases 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 12
- 206010003591 Ataxia Diseases 0.000 description 10
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 10
- 229940102566 valproate Drugs 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 9
- 239000001961 anticonvulsive agent Substances 0.000 description 8
- 206010015037 epilepsy Diseases 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 238000000692 Student's t-test Methods 0.000 description 7
- 230000036760 body temperature Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000012353 t test Methods 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000000573 anti-seizure effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000003390 teratogenic effect Effects 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 208000000060 Migraine with aura Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960003965 antiepileptics Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002964 excitative effect Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- -1 gums Chemical compound 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000002197 limbic effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 206010052787 migraine without aura Diseases 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100000378 teratogenic Toxicity 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 description 2
- 102100034033 Alpha-adducin Human genes 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000033001 Complex partial seizures Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000799076 Homo sapiens Alpha-adducin Proteins 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 101000629598 Rattus norvegicus Sterol regulatory element-binding protein 1 Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010043275 Teratogenicity Diseases 0.000 description 2
- 208000001407 Vascular Headaches Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960001903 ergotamine tartrate Drugs 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 230000001314 paroxysmal effect Effects 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 231100000211 teratogenicity Toxicity 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 206010054956 Phonophobia Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 229940124433 antimigraine drug Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940075960 desitin Drugs 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000015227 regulation of liquid surface tension Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9028198P | 1998-06-22 | 1998-06-22 | |
| PCT/US1999/014081 WO1999066920A1 (en) | 1998-06-22 | 1999-06-22 | The use of valproic acid analog for the treatment and prevention of migraine and affective illness |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG105163A BG105163A (en) | 2002-03-29 |
| BG63744B1 true BG63744B1 (bg) | 2002-11-29 |
Family
ID=22222101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105163A BG63744B1 (bg) | 1998-06-22 | 2001-01-17 | Използване на аналог на валпроева киселина за лечение и профилактика на мигрена и афективни заболявания |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6268396B1 (ko) |
| EP (1) | EP1089725A1 (ko) |
| JP (1) | JP2002518442A (ko) |
| KR (1) | KR20010071572A (ko) |
| CN (1) | CN1310622A (ko) |
| AU (2) | AU752192B2 (ko) |
| BG (1) | BG63744B1 (ko) |
| BR (1) | BR9911421A (ko) |
| CA (1) | CA2335641A1 (ko) |
| CZ (1) | CZ20004833A3 (ko) |
| HU (1) | HUP0102456A3 (ko) |
| IL (1) | IL140415A0 (ko) |
| MX (1) | MXPA00012808A (ko) |
| NO (1) | NO20006506L (ko) |
| PL (1) | PL345364A1 (ko) |
| SK (1) | SK19992000A3 (ko) |
| TR (2) | TR200003800T2 (ko) |
| WO (1) | WO1999066920A1 (ko) |
| ZA (1) | ZA200007652B (ko) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6104802A (en) | 1997-02-10 | 2000-08-15 | Genesys Telecommunications Laboratories, Inc. | In-band signaling for routing |
| DE60013811T2 (de) * | 1999-05-04 | 2005-11-17 | Keith R. Edwards | Intravenösen verabreichung von valproat zur behandlung von migränekopfschmerzen |
| CN1251758C (zh) | 2000-07-21 | 2006-04-19 | 特瓦制药工业有限公司 | 丙戊酸和2－丙基戊烯酸酰胺的衍生物在制备治疗双极情感障碍症躁狂病药物中的用途 |
| KR100851955B1 (ko) * | 2000-08-17 | 2008-08-12 | 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 | 통증 및/또는 두통 장애를 치료하거나 방지하기 위한 벨프로익산 아미드 및 2-벨프로에닉산 아미드 유도체의 용도 |
| US20020103110A1 (en) * | 2001-01-26 | 2002-08-01 | Spitzer A. Robert | System and method for rectal administration of medication for treatment of migraines |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| AU2003278565A1 (en) * | 2002-10-25 | 2004-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments |
| US20060166894A1 (en) * | 2002-11-29 | 2006-07-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Ace-inhibitors having antioxidant and no-donor activity |
| AU2003289782A1 (en) * | 2002-12-16 | 2004-07-09 | The University Of British Columbia | Valproic acid analogues and pharmaceutical compositions thereof |
| EP1543831A1 (en) * | 2003-12-18 | 2005-06-22 | Pfizer GmbH Arzneimittelwerk Gödecke | Pregabalin composition |
| WO2006012603A2 (en) * | 2004-07-22 | 2006-02-02 | Nps Pharmaceuticals, Inc. | Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases |
| EP1928807A4 (en) * | 2005-09-02 | 2011-05-04 | Picobella Llc | ONCOGENIC REGULATORS RNA FOR DIAGNOSIS AND THERAPY |
| US7459280B2 (en) * | 2006-02-27 | 2008-12-02 | Picobella, Llc | Methods for diagnosing and treating kidney cancer |
| US20080267977A1 (en) * | 2007-04-26 | 2008-10-30 | Friedrich-Alexander University Of Erlangen-Nuremberg | Combined immunological agent and sensitizing agent for the treatment of cancer |
| CA2872976A1 (en) * | 2012-05-08 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for the treatment of neurological disorders |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2442M (fr) | 1962-10-17 | 1964-04-06 | Henry Eugene | L'acide dipropylacétique et ses dérivés en tant que nouveuax médicaments dépresseurs du systeme nerveux central. |
| US3701729A (en) | 1970-06-01 | 1972-10-31 | Tenneco Chem | Oil-soluble mixed copper soap products |
| US3847956A (en) | 1973-04-06 | 1974-11-12 | Us Agriculture | 2-hydroperoxycarboxylic acids and their preparation |
| US3932285A (en) | 1973-10-03 | 1976-01-13 | Tenneco Chemicals, Inc. | Chromium salt compositions and a process for their production |
| US4025649A (en) | 1974-08-19 | 1977-05-24 | Labaz | Acetic acid derivatives having pharmacological activity and compositions containing the same |
| US4129599A (en) | 1975-04-28 | 1978-12-12 | The Board Of Trustees Of Leland Stanford Jr. University | A-Norsteroids |
| JPS5680116A (en) | 1979-12-05 | 1981-07-01 | Sanyo Electric Co Ltd | Manufacture of substrate for magnetic bubble |
| JPH0233704B2 (ja) | 1982-10-07 | 1990-07-30 | Takeda Chemical Industries Ltd | Chikanbinirukarubonsanjudotai |
| FR2599737B1 (fr) | 1986-06-10 | 1989-05-19 | Sanofi Sa | Procede pour la fixation de groupes alkyles, alkenyles, cycloalkyles ou aralkyles sur une chaine carbonee portant un groupement fonctionnel |
| JPH01135740A (ja) | 1987-11-24 | 1989-05-29 | Nippon Mining Co Ltd | 光学活性を有する２―アルキル―１―アルカン酸の製造方法 |
| US5021398A (en) | 1989-10-26 | 1991-06-04 | Amp Incorporated | Method of forming patterned oxide superconducting films |
| US5102913A (en) * | 1991-07-01 | 1992-04-07 | Halikas James A | Treatment for cocaine use employing valproic acid |
| DE4231085A1 (de) * | 1992-09-12 | 1994-03-17 | Desitin Arzneimittel Gmbh | VPA-analoge Antiepileptika |
| CA2144081C (en) | 1992-09-16 | 2004-11-30 | Filip Roos | Protection against liver damage by hgf |
| ATE157118T1 (de) | 1992-11-30 | 1997-09-15 | Procter & Gamble | Hochschäumende waschmittelzusammensetzungen mit speziell ausgewählten seifen |
| JP3304459B2 (ja) | 1992-12-18 | 2002-07-22 | 松下電器産業株式会社 | 電解コンデンサ駆動用電解液およびそれを用いた電解コンデンサ |
| DK0632008T3 (da) | 1993-06-01 | 1998-09-23 | Ono Pharmaceutical Co | Pentansyrederivater |
| US5503830A (en) | 1993-09-10 | 1996-04-02 | Petrovax, L.L.C. | Compounds having immunostimulating activity and methods of use thereof |
| WO1995033044A1 (en) | 1994-05-27 | 1995-12-07 | The Procter & Gamble Company | Liquid laundry detergent compositions comprising specially selected soaps |
| US5681854A (en) | 1995-11-22 | 1997-10-28 | Alcon Laboratories, Inc. | Use of aliphatic carboxylic acid derivatives in ophthalmic disorders |
| IT1283489B1 (it) | 1996-07-23 | 1998-04-21 | Chiesi Farma Spa | Ammidi di alfa-amminoacidi,loro preparazione e loro impiego terapeutico |
-
1999
- 1999-06-22 WO PCT/US1999/014081 patent/WO1999066920A1/en not_active Application Discontinuation
- 1999-06-22 CA CA002335641A patent/CA2335641A1/en not_active Abandoned
- 1999-06-22 JP JP2000555606A patent/JP2002518442A/ja active Pending
- 1999-06-22 TR TR2000/03800T patent/TR200003800T2/xx unknown
- 1999-06-22 AU AU47071/99A patent/AU752192B2/en not_active Ceased
- 1999-06-22 IL IL14041599A patent/IL140415A0/xx unknown
- 1999-06-22 EP EP99930555A patent/EP1089725A1/en not_active Withdrawn
- 1999-06-22 MX MXPA00012808A patent/MXPA00012808A/es unknown
- 1999-06-22 US US09/337,986 patent/US6268396B1/en not_active Expired - Fee Related
- 1999-06-22 CN CN99808955A patent/CN1310622A/zh active Pending
- 1999-06-22 HU HU0102456A patent/HUP0102456A3/hu unknown
- 1999-06-22 SK SK1999-2000A patent/SK19992000A3/sk unknown
- 1999-06-22 PL PL99345364A patent/PL345364A1/xx not_active Application Discontinuation
- 1999-06-22 KR KR1020007014630A patent/KR20010071572A/ko not_active Application Discontinuation
- 1999-06-22 BR BR9911421-6A patent/BR9911421A/pt not_active IP Right Cessation
- 1999-06-22 CZ CZ20004833A patent/CZ20004833A3/cs unknown
- 1999-06-27 TR TR2001/03249T patent/TR200103249T2/xx unknown
- 1999-06-28 AU AU52071/99A patent/AU5207199A/en not_active Abandoned
-
2000
- 2000-12-19 ZA ZA200007652A patent/ZA200007652B/en unknown
- 2000-12-20 NO NO20006506A patent/NO20006506L/no not_active Application Discontinuation
-
2001
- 2001-01-17 BG BG105163A patent/BG63744B1/bg unknown
- 2001-04-23 US US09/840,376 patent/US6458840B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6268396B1 (en) | 2001-07-31 |
| US20010031789A1 (en) | 2001-10-18 |
| BG105163A (en) | 2002-03-29 |
| IL140415A0 (en) | 2002-02-10 |
| WO1999066920A1 (en) | 1999-12-29 |
| AU752192B2 (en) | 2002-09-12 |
| EP1089725A1 (en) | 2001-04-11 |
| HUP0102456A2 (hu) | 2001-10-28 |
| MXPA00012808A (es) | 2002-04-24 |
| CA2335641A1 (en) | 1999-12-29 |
| TR200003800T2 (tr) | 2001-06-21 |
| AU5207199A (en) | 2000-01-24 |
| ZA200007652B (en) | 2002-03-19 |
| PL345364A1 (en) | 2001-12-17 |
| HUP0102456A3 (en) | 2003-07-28 |
| JP2002518442A (ja) | 2002-06-25 |
| NO20006506D0 (no) | 2000-12-20 |
| AU4707199A (en) | 2000-01-10 |
| SK19992000A3 (sk) | 2001-08-06 |
| KR20010071572A (ko) | 2001-07-28 |
| US6458840B2 (en) | 2002-10-01 |
| BR9911421A (pt) | 2001-03-27 |
| TR200103249T2 (tr) | 2002-05-21 |
| NO20006506L (no) | 2001-02-21 |
| CZ20004833A3 (cs) | 2002-01-16 |
| CN1310622A (zh) | 2001-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3693258B2 (ja) | イソブチルｇａｂａまたはその誘導体を含有する鎮静剤 | |
| CA2498260C (en) | Pharmaceutical formulations of modafinil | |
| KR100785182B1 (ko) | 수면 장애를 위한 가바펜틴 유사체 | |
| KR100557852B1 (ko) | 이통증 또는 다른 여러가지 타입의 만성동통 또는 환상통을 치료하는데 쓰이는 의약 조성물 | |
| BG63744B1 (bg) | Използване на аналог на валпроева киселина за лечение и профилактика на мигрена и афективни заболявания | |
| US20020058656A1 (en) | Triple drug therapy for the treatment and prevention of acute or chronic pain | |
| US20040029941A1 (en) | Zonisamide use in obesity and eating disorders | |
| CZ297284B6 (cs) | Farmaceutiký prostredek pro lécbu syndromu neklidných nohou | |
| HUE033180T2 (en) | Peptide compounds for the treatment of difficult to cure epileptic diseases | |
| EP2129383A1 (en) | Treatment of anxiety disorders with minocycline | |
| RU2166318C2 (ru) | Флюпиртин - действующее вещество медицинских и фармакологических средств с активностью антагониста эксайторных аминокислот | |
| EA019354B1 (ru) | Применение димирацетама для лечения хронической боли | |
| NZ506020A (en) | Use of pharmaceutical combinations containing tramadol and an antiemetic | |
| PT1274414E (pt) | Administração nasal de metoclopramida para o tratamento de gastroparesia | |
| ES2390225T3 (es) | Combinación del analéptico modafinilo y de un antidepresivo para el tratamiento de la depresión | |
| US7915262B2 (en) | Combination preparations comprising SLV308 and a dopamine agonist | |
| MXPA06015196A (es) | Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide. | |
| TW200528098A (en) | Treatment of insomnia in human patients | |
| ES2425045T3 (es) | Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa | |
| WO2007144421A1 (en) | Combination preparations comprising slv308 and a l-dopa | |
| EP2891491A1 (en) | Use of (r)-phenylpiracetam for the treatment of sleep disorders | |
| JPH0645539B2 (ja) | 鎮痛剤 | |
| JP2003525241A (ja) | 機能性胃腸疾患治療用トラマドール | |
| US20100152231A1 (en) | Compositions Useful For Treating Irritable Bowel Syndrome |